시장보고서
상품코드
2105805

저분자 의약품 API CDMO 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

Global Small Molecule Innovator API CDMO Market Size, Share, Trends & Growth Analysis Report 2026-2034

발행일: | 리서치사: 구분자 Value Market Research | 페이지 정보: 영문 177 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트 발췌나 도표 복사는 Value Market Research를 인용하여야 하며, 사내용 문서에 한해 가능합니다. 인쇄는 가능하지만, 인쇄물은 구매한 조직 내에서만 보관해야 합니다. 또한, 보고서 내용을 AI 도구나 자동 분석 플랫폼에 업로드하거나, 외부 공개 및 상업적 이용은 금지되어 있습니다.
US $ 3,920 금액 안내 화살표 ₩ 5,612,000
PDF & Excel (10-user License) help
PDF & Excel 보고서를 동일 기업내 10명까지 이용할 수 있는 라이선스입니다. 텍스트 발췌나 도표 복사는 Value Market Research를 인용하여야 하며, 사내용 문서에 한해 가능합니다. 인쇄는 가능하지만, 인쇄물은 구매한 조직 내에서만 보관해야 합니다. 또한, 보고서 내용을 AI 도구나 자동 분석 플랫폼에 업로드하거나, 외부 공개 및 상업적 이용은 금지되어 있습니다.
US $ 4,730 금액 안내 화살표 ₩ 6,771,000
PDF & Excel (Corporate User License) help
PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다.
US $ 7,430 금액 안내 화살표 ₩ 10,637,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 저분자 의약품 API CDMO 시장 규모는 2025년 296억 6,000만 달러에서 2034년에는 532억 1,000만 달러에 달할 것으로 예측되며, 2026년부터 2034년까지 CAGR 6.71%로 성장할 것으로 전망됩니다. 전 세계 저분자 신약 개발용 API CDMO 시장은 의약품 제조 분야의 아웃소싱 추세가 강화됨에 따라 강력한 성장을 이루고 있습니다. 신약 개발 기업들은 비용 절감과 의약품 개발 기간 단축을 위해 수탁 개발·제조 기관(CDMO)과 제휴하고 있습니다. 복잡한 저분자 의약품 및 특수 API에 대한 수요 증가가 시장 확대를 주도하고 있습니다. 또한, 규제 요건의 강화도 기업들이 경험이 풍부한 CDMO 파트너에 의존하도록 부추기고 있습니다.

주요 성장 요인으로는 신약 승인 건수의 증가와 의약품 파이프라인의 확대를 꼽을 수 있습니다. CDMO는 공정 최적화, 생산 규모 확대, 규제 준수 관련 전문 지식을 제공하고 있습니다. 연구개발비 증가와 효율 개선에 대한 집중이 아웃소싱 활동을 촉진하고 있습니다. 더욱이 유연한 제조 능력과 첨단 기술에 대한 접근성에 대한 수요가 이 분야의 지속적인 성장을 뒷받침하고 있습니다.

앞으로 제약사들이 전략적 제휴를 우선시함에 따라 시장은 더욱 확대될 것으로 예상됩니다. 연속 제조 및 그린 케미스트리 분야의 기술 발전으로 생산 효율이 향상될 것입니다. 신흥 시장은 비용 면에서의 우위와 숙련된 인력 확보가 가능하다는 점에서 매력적인 아웃소싱 거점으로 부상하고 있습니다. 저분자 치료제의 혁신이 지속되는 가운데, CDMO의 역할은 점점 더 중요해질 것입니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 저분자 의약품 API CDMO 시장 : 스테이지 유형별

제5장 세계의 저분자 의약품 API CDMO 시장 : 고객 유형별

제6장 세계의 저분자 의약품 API CDMO 시장 : 치료 분야별

제7장 세계의 저분자 의약품 API CDMO 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

KSM 26.08.12

The global small molecule innovator API CDMO market size is expected to reach USD 53.21 Billion in 2034 from USD 29.66 Billion in 2025, growing at a CAGR of 6.71 during 2026-2034.The Global Small Molecule Innovator API CDMO Market is experiencing strong growth due to increasing outsourcing trends in pharmaceutical manufacturing. Innovator companies are partnering with Contract Development and Manufacturing Organizations (CDMOs) to reduce costs and accelerate drug development timelines. Rising demand for complex small molecule drugs and specialty APIs is driving market expansion. Growing regulatory requirements also encourage companies to rely on experienced CDMO partners.

Key drivers include the rising number of new drug approvals and expanding pharmaceutical pipelines. CDMOs provide expertise in process optimization, scale-up production, and regulatory compliance. Increasing R&D expenditure and focus on efficiency improvements enhance outsourcing activities. Additionally, the need for flexible manufacturing capabilities and access to advanced technologies supports sustained growth in the sector.

Looking ahead, the market is expected to grow further as pharmaceutical companies prioritize strategic collaborations. Technological advancements in continuous manufacturing and green chemistry will improve production efficiency. Emerging markets are becoming attractive outsourcing hubs due to cost advantages and skilled labor availability. As innovation in small molecule therapeutics continues, the role of CDMOs will remain increasingly critical.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Stage Type

  • Preclinical
  • Clinical
  • Commercial

By Customer Type

  • Pharmaceutical
  • Biotechnology

By Therapeutic Area

  • Cardiovascular Diseases
  • Oncology
  • Neurology
  • Metabolic Disorders
  • Infectious Diseases
  • Respiratory Disorders
  • Others

COMPANIES PROFILED

  • Lonza Group AG, Catalent, Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim International GmbH, Siegfried Holding AG, Cambrex Corporation, Recipharm AB, Piramal Pharma Solutions, Aenova Group, Asymchem Laboratories

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY STAGE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Stage Type
  • 4.2. Preclinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY CUSTOMER TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Customer Type
  • 5.2. Pharmaceutical Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Biotechnology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Therapeutic Area
  • 6.2. Cardiovascular Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Respiratory Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Stage Type
    • 7.2.2 By Customer Type
    • 7.2.3 By Therapeutic Area
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Stage Type
    • 7.3.2 By Customer Type
    • 7.3.3 By Therapeutic Area
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Stage Type
    • 7.4.2 By Customer Type
    • 7.4.3 By Therapeutic Area
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Stage Type
    • 7.5.2 By Customer Type
    • 7.5.3 By Therapeutic Area
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Stage Type
    • 7.6.2 By Customer Type
    • 7.6.3 By Therapeutic Area
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL SMALL MOLECULE INNOVATOR API CDMO INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Lonza Group AG
    • 9.2.2 CatalentInc
    • 9.2.3 Thermo Fisher Scientific Inc
    • 9.2.4 Boehringer Ingelheim International GmbH
    • 9.2.5 Siegfried Holding AG
    • 9.2.6 Cambrex Corporation
    • 9.2.7 Recipharm AB
    • 9.2.8 Piramal Pharma Solutions
    • 9.2.9 Aenova Group
    • 9.2.10 Asymchem Laboratories
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기